阿尔茨海默氏症目标识别的演变:走向人工智能和细胞智能的融合
Gayle Wittenberg1, Fiona Elwood2, Andrea Houghton3
1Neuroscience R&D, Johnson & Johnson Innovative Medicine, Titusville, NJ, USA.
The journal of prevention of Alzheimer's disease
|December 1, 2025
概括
人工智能 (AI) 和人类细胞模型正在彻底改变阿尔茨海默病 (AD) 研究. 人类,人工和细胞智能的这种融合为了解疾病机制和开发有效疗法提供了新的希望.
科学领域:
- 神经科学是一个神经科学.
- 计算生物学 计算生物学
- 遗传学 遗传学 是一个
背景情况:
- 最近的科学进步包括大规模复杂化,人口队列,计算能力,人工智能模型和人类细胞模型.
- 这些进步产生了大量的数据集,使得可以更深入地探索阿尔茨海默氏症 (AD) 生物学.
- 多omics数据和AI的整合对于剖析AD复杂性至关重要.
研究的目的:
- 通过了解随着时间的推移,基因,细胞和环境相互作用的功能障碍的出现,探索阿尔茨海默病的根本原因.
- 通过从疾病状态向后工作来推进治疗发现,以确定上游干预措施.
- 利用人类细胞模型验证人工智能预测的目标和测试干预措施.
主要方法:
- 使用大规模的多omics数据集和先进的人工智能 (AI) 模型.
- 应用人类诱导多能干细胞 (iPSC) 和其他人类细胞模型来映射表型的干扰.
- 整合人类,人工和细胞智能,以实现协作研究方法.
主要成果:
- 人工智能能够更深入地了解阿尔茨海默病 (AD) 的生物学及其根本原因.
- 人类细胞模型为验证人工智能驱动的治疗目标提供了一个平台.
- 人工智能和细胞模型之间的协同作用加速了干预措施的发现.
结论:
- 人类,人工和细胞智能的融合代表了阿尔茨海默病 (AD) 研究的新前沿.
- 这种协作方法有望带来重大科学创新和治疗进步.
- 结合这些智能为开发新型治疗和推进人类健康提供了希望.
更多相关视频
09:47Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
1.7K
11:57Saccharomyces cerevisiae Models of Alzheimer's Disease to Screen Genes, Mutations, and Chemicals Affecting Amyloid Beta Production by γ-Secretase
Published on: June 24, 2025
468
相关概念视频
Alzheimer's Disease: Treatment
764
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
764
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Amyloid Fibrils
11.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
11.5K
